Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：3

作者：

Bhutani, Manisha ^{[1
]}

Robinson, Myra ^{[2
]}

Atrash, Shebli ^{[1
]}

Paul, Barry ^{[1
]}

Pineda-Roman, Mauricio ^{[1
]}

Foureau, David ^{[3
]}

Varga, Cindy ^{[1
]}

Friend, Reed ^{[1
]}

Begic, Xhevahire ^{[4
]}

Norek, Sarah ^{[4
]}

Drennan, Tiffany ^{[5
]}

Anderson, Michelle B. ^{[6
]}

Symanowski, James ^{[2
]}

Voorhees, Peter M. ^{[7
]}

Usmani, Saad Z. ^{[8
]}

机构：

[1] Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA

[2] Atrium Hlth, Levine Canc Inst, Dept Canc Biostat, Charlotte, NC USA

[3] Atrium Hlth, Levine Canc Inst, Immune Monitoring Core Lab, Charlotte, NC USA

[4] Atrium Hlth, Levine Canc Inst, Sponsored Res Coordinating Ctr, Charlotte, NC USA

[5] Atrium Hlth, Levine Canc Inst, Clin Trials Unit, Charlotte, NC USA

[6] Atrium Hlth, Levine Canc Inst, Biostat & Data Sci, Charlotte, NC USA

[7] Wake Forest Univ, Sch Med, Atrium Hlth, Dept Hematol Oncol & Blood Disorders,Levine Canc, Charlotte, NC USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Oncol, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174972

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) [J].

Nooka, Ajay K. ;

Kaufman, Jonathan L. ;

Rodriguez, Cesar ;

Jakubowiak, Andrzej ;

Efebera, Yvonne A. ;

Reeves, Brandi ;

Wildes, Tanya M. ;

Holstein, Sarah A. ;

Anderson, Larry D., Jr. ;

Badros, Ashraf Z. ;

Shune, Leyla O. ;

Chari, Ajai ;

Pei, Huiling ;

Cortoos, Annelore ;

Patel, Sharmila ;

Lin, Thomas S. ;

Richardson, Paul G. ;

Usmani, Saad ;

Voorhees, Peter M. .

BLOOD, 2022, 140 :10154-10156

[32] Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) [J].

van Vliet, Martin ;

Jasielec, Jagoda ;

Dytfeld, Dominik ;

Vij, Ravi ;

Dumee, Belinda ;

Bosman, Lizanne ;

deBest, Leonie C. M. ;

Alonge, Mattina ;

Rosebeck, Shaun ;

Kandarpa, Malathi ;

McDonnell, Kathryn ;

Griffith, Kent A. ;

van Beers, Erik H. ;

Jakubowiak, Andrzej .

BLOOD, 2014, 124 (21)

[33] Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial [J].

Gay, Francesca ;

Musto, Pellegrino ;

Rota-Scalabrini, Delia ;

Bertamini, Luca ;

Belotti, Angelo ;

Galli, Monica ;

Offidani, Massimo ;

Zamagni, Elena ;

Ledda, Antonio ;

Grasso, Mariella ;

Ballanti, Stelvio ;

Spadano, Antonio ;

Cea, Michele ;

Patriarca, Francesca ;

D'Agostino, Mattia ;

Capra, Andrea ;

Giuliani, Nicola ;

de Fabritiis, Paolo ;

Aquino, Sara ;

Palmas, Angelo ;

Gamberi, Barbara ;

Zambello, Renato ;

Petrucci, Maria Teresa ;

Corradini, Paolo ;

Cavo, Michele ;

Boccadoro, Mario .

LANCET ONCOLOGY, 2021, 22 (12) :1705-1720

[34] Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma The MANHATTAN Nonrandomized Clinical Trial [J].

Landgren, Ola ;

Hultcrantz, Malin ;

Diamond, Benjamin ;

Lesokhin, Alexander M. ;

Mailankody, Sham ;

Hassoun, Hani ;

Tan, Carlyn ;

Shah, Urvi A. ;

Lu, Sydney X. ;

Salcedo, Meghan ;

Werner, Kelly ;

Rispoli, Jenna ;

Caple, Julia ;

Sams, Allison ;

Verducci, Dennis ;

Jones, Katie ;

Concepcion, Isabel ;

Ciardello, Amanda ;

Chansakul, Aisara ;

Schlossman, Julia ;

Tavitian, Elizabet ;

Shekarkhand, Tala ;

Harrison, Angela ;

Piacentini, Casey ;

Rustad, Even H. ;

Yellapantula, Venkata ;

Maclaughlan, Kylee ;

Maura, Francesco ;

Landau, Heather J. ;

Scordo, Michael ;

Chung, David J. ;

Shah, Gunjan ;

Lahoud, Oscar B. ;

Thoren, Katie ;

Murata, Kazunori ;

Ramanathan, Lakshmi ;

Arcila, Maria E. ;

Ho, Caleb ;

Roshal, Mikhail ;

Dogan, Ahmet ;

Derkach, Andriy ;

Giralt, Sergio A. ;

Korde, Neha .

JAMA ONCOLOGY, 2021, 7 (06) :862-868

[35] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy [J].

Kaufman, Jonathan L. ;

Laubach, Jacob P. ;

Sborov, Douglas ;

Reeves, Brandi ;

Rodriguez, Cesar ;

Chari, Ajai ;

Silbermann, Rebecca W. ;

Costa, Luciano J. ;

Anderson, Larry D., Jr. ;

Nathwani, Nitya ;

Shah, Nina ;

Efebera, Yvonne A. ;

Holstein, Sara A. ;

Costello, Caitlin ;

Jakubowiak, Andrzej ;

Wildes, Tanya M. ;

Orlowski, Robert Z. ;

Shain, Kenneth H. ;

Cowan, Andrew J. ;

Lutska, Yana ;

Bobba, Padma ;

Pei, Huiling ;

Ukropec, Jon ;

Vermeulen, Jessica ;

Lin, Thomas S. ;

Richardson, Paul G. ;

Voorhees, Peter M. .

BLOOD, 2020, 136

[36] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance [J].

Kaufman, Jonathan L. ;

Laubach, Jacob P. ;

Sborov, Douglas ;

Reeves, Brandi ;

Rodriguez, Cesar ;

Chari, Ajai ;

Silbermann, Rebecca W. ;

Costa, Luciano J. ;

Anderson, Larry D., Jr. ;

Nathwani, Nitya ;

Shah, Nina ;

Efebera, Yvonne A. ;

Holstein, Sara A. ;

Costello, Caitlin ;

Jakubowiak, Andrzej ;

Wildes, Tanya M. ;

Orlowski, Robert Z. ;

Shain, Kenneth H. ;

Cowan, Andrew J. ;

Lutska, Yana ;

Bobba, Padma ;

Pei, Huiling ;

Ukropec, Jon ;

Vermeulen, Jessica ;

Lin, Thomas S. ;

Richardson, Paul G. ;

Voorhees, Peter M. .

BLOOD, 2021, 138

[37] Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM). [J].

Derman, Benjamin Avi ;

Zonder, Jeffrey A. ;

Kansagra, Ankit J. ;

Grinblatt, David L. ;

Narula, Sunil ;

Rayani, Shayan ;

Stefka, Andrew T. ;

Jiang, Ken ;

Major, Sarah ;

Wolfe, Brittany ;

Whelan, Megan ;

Libao, Bernadette ;

McIver, Amanda ;

Andreatos, Evangelia ;

Juergens, Daniel ;

Alcantar, Luis ;

Karrison, Theodore ;

Bishop, Michael Russell ;

Jasielec, Jagoda ;

Jakubowiak, Andrzej J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[38] Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. [J].

Korde, Neha ;

Zingone, Adriana ;

Kwok, Mary ;

Manasanch, Elisabet E. ;

Bhutani, Manisha ;

Costello, Rene ;

Yancey, Mary Ann ;

Mulquin, Marcia ;

Calvo, Katherine R. ;

Maric, Irina ;

Tembhare, Prashant ;

Yuan, Constance ;

Stetler-Stevenson, Maryalice ;

Arthur, Diane Carol ;

Choyke, Peter L. ;

Kurdziel, Karen A. ;

Steinberg, Seth M. ;

Raffeld, Mark ;

Roschewski, Mark J. ;

Landgren, Ola .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[39] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS [J].

Crusoe, Edvan De Queiroz ;

Leal, Joanna ;

Santos, Juliana Andrade ;

de Melo Santos, Herbert Henrique ;

Santos, Allan de Souza ;

Lucas, Larissa Ferreira ;

Almeida, Alessandro de M. ;

Chaves, Marcos ;

Dutra, Daniela Dourado ;

Hungria, Vania T. M. ;

Salvino, Marco Aurelio ;

Arruda, Maria da Gloria B. .

BLOOD, 2022, 140 :7699-7700

[40] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS). [J].

Sonneveld, Pieter ;

Broijl, Annemiek ;

Gay, Francesca ;

Boccadoro, Mario ;

Einsele, Hermann ;

Blade, Joan ;

Dimopoulos, Meletios A. ;

Delforge, Michel ;

Spencer, Andrew ;

Hajek, Roman ;

Schjesvold, Fredrik ;

Lonergan, Sarah ;

Smith, Elena ;

Carson, Robin L. ;

Crist, Wendy ;

Garvin, Wendy S. ;

Vermeulen, Jessica ;

Moreau, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →